Abstract: Disclosed are compounds having the formula (Formula I)): wherein R1, R2, R3 and Z are as defined herein, and methods of making and using the same.
Type:
Grant
Filed:
August 17, 2012
Date of Patent:
March 28, 2017
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Michael Jonathan Bury, Linda N. Casillas, Adam K. Charnley, Michael P. Demartino, Xiaoyang Dong, Patrick M. Eidam, Pamela A. Haile, Robert W. Marquis, Jr., Joshi M. Ramanjulu, Joseph J. Romano, Ami Lakdawala Shah, Robert R. Singhaus, Jr., Gren Wang
Abstract: Disclosed are compounds having the formula: wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A, L, and B are as defined herein, and methods of making and using the same.
Type:
Grant
Filed:
February 14, 2014
Date of Patent:
January 31, 2017
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Philip Anthony Harris, Bryan Wayne King
Abstract: A compound of formula (I): or a pharmaceutically acceptable salt thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation.
Type:
Application
Filed:
July 1, 2014
Publication date:
December 22, 2016
Applicant:
Glaxosmithkline Intellectual Property Development Limited
Inventors:
Sebastien Andre CAMPOS, John David HARLING, Afjal Hussain MIAH, Ian Edward, David SMITH
Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.
Type:
Application
Filed:
December 17, 2014
Publication date:
November 3, 2016
Applicant:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors:
Anne Marie Jeanne BOUILLOT, Olivier MIRGUET, John LIDDLE, Anne Louise WALKER
Abstract: The present invention relates to novel analogs of PYY that have an improved therapeutic profile when compared to native human PYY. These novel PYY analogs are useful in the treatment of obesity, diabetes, and other disorders.
Type:
Grant
Filed:
April 30, 2014
Date of Patent:
September 13, 2016
Assignee:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors:
Steven Thomas Dock, Andrew James Carpenter, Robert Neil Hunter, III, Yulin Wu, Ved P. Srivastava
Abstract: The present invention is directed to compounds and pharmaceutically acceptable salts thereof which are inhibitors of the activity or function of the phosphoinositide 3?OH kinase family (hereinafter PI3K) for use in the treatment or prevention of respiratory infections, the treatment of airway damage, and/or the prevention of airway injury in patients with a PI3K? mutation.
Type:
Application
Filed:
October 15, 2014
Publication date:
September 8, 2016
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: The invention relates to activators of soluble guanylate cyclase and their use in pharmaceutical compositions, primarily topically administered ophthalmic compositions. The pharmaceutical compositions are useful for reducing intraocular pressure in animals of the mammalian species.
Type:
Application
Filed:
September 5, 2014
Publication date:
July 28, 2016
Applicant:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Krista B. GOODMAN, Achim Hans-Peter KRAUSS, Anne-Charlotte LE MONNIER DE GOUVILLE, Nerina DODIC
Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
July 5, 2016
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: The present invention relates to novel 3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
Type:
Grant
Filed:
January 23, 2014
Date of Patent:
March 29, 2016
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: A system is provided that can include a processing device and a memory device in which instructions executable by the processing device are stored for causing the processing device to receive sensor data indicating a physiological characteristic of a patient. The instructions can also cause the processing device to electronically transform the sensor data into a risk score representative of a risk to the patient for a negative outcome by applying the physiological characteristic to at least one predictive model received from a predictive model database. The instructions can also cause the processing device to electronically determine a corrective option for reducing the risk by applying the physiological characteristic to a plurality of rules received from a rules database. The instructions can also cause the processing device to configure a display device to output a graphical user interface (GUI) comprising the risk score and the corrective option.
Type:
Application
Filed:
August 12, 2015
Publication date:
March 17, 2016
Applicants:
Community Care of North Carolina, Inc., GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Troy Trygstad, Alan Menius, Jeffery L. Painter, JR.
Abstract: Compounds of formula (I) inhibit HDAC activity: wherein A, B and D independently represent ?C— or ?N—; W is a divalent radical —CH?CH— or CH2CH2—; R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.
Type:
Grant
Filed:
July 7, 2014
Date of Patent:
March 1, 2016
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Alan Hornsby Davidson, David Festus Charles Moffat, Francesca Ann Day, Alastair David Graham Donald
Abstract: Disclosed are 4-amino-2-butenamides of Formula (I) having pharmacological activity, pharmaceutical compositions containing them, and methods for the treatment of diseases mediated by the cathepsin C enzyme such as chronic obstructive pulmonary disease.
Type:
Grant
Filed:
August 21, 2014
Date of Patent:
November 17, 2015
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Christopher E. Neipp, Michael R. Palovich
Abstract: The present disclosure relates to antigen binding proteins, such as antibodies, that bind to HER3, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present disclosure also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with breast cancer, ovarian cancer, prostate cancer, bladder cancer, pancreatic, gastric, melanoma and other cancers that overexpress HER3.
Type:
Grant
Filed:
September 2, 2011
Date of Patent:
July 21, 2015
Assignee:
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors:
Neil James Clarke, Kyung Oh Johanson, Zdenka Ludmila Jonak, Alexander H. Taylor, Christopher B. Hopson, Stephen H. Trulli, Zdenka Haskova, Judithann M. Lee, John R. White, Yu Xue
Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
Type:
Grant
Filed:
December 9, 2014
Date of Patent:
May 19, 2015
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.
Type:
Grant
Filed:
August 12, 2011
Date of Patent:
April 21, 2015
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
Haren Arulanantham, Thil Dinuk Batuwangala, Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon
Abstract: Compounds of formula (I), and salts, N-oxides, hydrates and solvates thereof are histone deacetylase inhibitors and are useful in the treatment of cell proliferative diseases, including cancers: wherein Q, V and W independently represent —N? or —C?; B is a divalent radical selected from (B1), (B2), (B3), (B4), (B5) and (B6). wherein the bond marked * is linked to the ring containing Q, V and W through -[Linker1]- and the bond marked ** is linked to A through -[Linker2]-; A is an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system; -[Linker1]- and -[Linker2]- independently represent a bond, or a divalent linker radical; and R is (a) a radical of formula R1R2CHNH—Y-L1-X1—(CH2)z— or (b) a radical of formula R-L1-Y1—(CH2)z—.
Type:
Grant
Filed:
October 30, 2006
Date of Patent:
February 24, 2015
Assignee:
GlaxoSmithKline Intellectual Property Development Limited
Inventors:
David Charles Festus Moffat, Sanjay Ratilal Patel, Francesca Ann Day, Andrew James Belfield, Alistair David Graham Donald, Alan Hornsby Davidson, Alan Hastings Drummond
Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
January 20, 2015
Assignee:
GlaxoSmithKline Intellectual Property Development Limited